Diabetes

Lowest glucose variability for insulin + GLP-1 RA in T2DM

(HealthDay)—For patients with type 2 diabetes, the lowest glucose variability (GV) and hypoglycemia is seen for patients using basal insulin + glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), according to a study ...

Diabetes

Glucagon-like peptide-1 receptor agonists beneficial as add-on

(HealthDay)—Lixisenatide and glulisine as add-on to basal insulin result in a reduction in glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes, according to a study published online June 22 in Diabetes Care.

Diabetes

Varying safety of add-on second-line T2DM treatments

(HealthDay)—For patients with type 2 diabetes who are taking metformin, the risk of cardiovascular events and mortality varies with the addition of different second-line therapies, according to a study published online ...

Diabetes

GLP-1 receptor agonists can manage postprandial glucose

(HealthDay)—Glucagon-like peptide 1 (GLP-1) receptor agonists appear beneficial for postprandial glucose management in type 2 diabetes, according to a report published in the October issue of Clinical Diabetes.

page 1 from 3